Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Cytosorbents (CTSO) over the last 3 years, with Q2 2025 value amounting to $965000.0.

  • Cytosorbents' Other Accumulated Expenses changed N/A to $965000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $965000.0, marking a year-over-year change of. This contributed to the annual value of $812000.0 for FY2024, which is 1810.76% down from last year.
  • As of Q2 2025, Cytosorbents' Other Accumulated Expenses stood at $965000.0.
  • Cytosorbents' 5-year Other Accumulated Expenses high stood at $991545.0 for Q4 2023, and its period low was $796925.0 during Q1 2025.
  • For the 3-year period, Cytosorbents' Other Accumulated Expenses averaged around $891367.5, with its median value being $888500.0 (2024).
  • Within the past 5 years, the most significant YoY rise in Cytosorbents' Other Accumulated Expenses was 1810.76% (2024), while the steepest drop was 1810.76% (2024).
  • Over the past 3 years, Cytosorbents' Other Accumulated Expenses (Quarter) stood at $991545.0 in 2023, then decreased by 18.11% to $812000.0 in 2024, then increased by 18.84% to $965000.0 in 2025.
  • Its Other Accumulated Expenses stands at $965000.0 for Q2 2025, versus $796925.0 for Q1 2025 and $812000.0 for Q4 2024.